This clinical study focuses on testing a medication called deucrictibant for people with Hereditary Angioedema (HAE), a rare genetic condition that causes unexpected episodes of severe swelling in various parts of the body. These swelling attacks can affect the skin, digestive tract, and airways, potentially causing significant discomfort and health risks.
The purpose of this research is to evaluate how safe and effective deucrictibant extended-release tablets are when taken regularly to prevent HAE attacks. The medication will be given as a 40 mg oral tablet that patients take to help reduce the frequency and severity of swelling episodes.
This is a long-term study where participants will receive the study medication and be monitored for any side effects and changes in their condition. During the study, patients will continue to have access to their usual emergency medications for treating sudden HAE attacks. Participants will need to keep track of their symptoms and complete various questionnaires about their quality of life and how well the treatment is working for them.
Austria 
Bulgaria 
France 
Germany 
Hungary 
Ireland 
Italy 
Poland 
Romania 
Slovakia 
Spain 
